Target intelligence / Profile preview

Caricain

Molecular classification
Enzyme, Cysteine protease, Papain-like protease, Hydrolase
01

Overview

Caricain, historically referred to as Papaya peptidase A, is a highly basic cysteine protease isolated from the latex of the papaya plant (Carica papaya). It is a prominent member of the C1 family of peptidases (papain-like) and is one of the most abundant enzymes in papaya latex, alongside papain and chymopapain. Caricain is characterized by its broad proteolytic activity and a unique ability to efficiently cleave peptide bonds involving proline and glutamine residues. This specific activity makes it a valuable therapeutic agent for the degradation of immunogenic gluten peptides, which are responsible for triggering inflammatory immune responses in individuals with celiac disease. Beyond its role in digestive health, caricain is utilized in topical pharmaceutical preparations for the debridement of necrotic tissue in chronic wounds and ulcers. While it is used as a therapeutic enzyme (e.g., in the supplement GluteGuard), its application requires caution due to potential cross-reactivity in individuals with latex allergies and possible interactions with anticoagulant therapies.

Other names
CaricainPapaya peptidase IIPapaya proteinase IIIPapaya proteinase omegaProteinase omegaPapaya proteinase AChymopapain S
02

Mechanism of action

Enzymatic hydrolysis of peptide bonds; specifically targets and neutralizes immunogenic proline- and glutamine-rich sequences in gluten to prevent the activation of T-cells in the intestinal mucosa.

03

Biological functions

ProteolysisCysteine-type endopeptidase activityProtein digestionDefense response to pests
04

Disease associations

Celiac diseaseDigestive disorderWound healingInflammationInfection
05

Safety considerations

AnaphylaxisLatex-fruit syndrome (cross-reactivity with latex allergens)Esophageal irritation and damage (with high concentrations or unripe fruit ingestion)Increased risk of bleeding and bruising when combined with warfarin
06

Interacting drugs

E-64

4 more in the full profile.

07

Biomarkers

Urinary gluten immunogenic peptides (GIP)Anti-tissue transglutaminase (tTG) antibodiesMarsh score (histopathology)Wound granulation tissue

Beyond the preview

Go deeper on Caricain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caricain.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call